IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease
MONTREAL, July 03, 2024 (GLOBE NEWSWIRE) — IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of IntelGenx Technologies Corp.) (OTCQB:IGXT; TSX:IGX), has successfully completed the BUENA Alzheimer’s disease (AD) study. The BUENA study was designed as a Phase 2a proof of concept study to investigate the extent to which different doses of Montelukast (MTK) could improve cognition in adults with AD as well as to provide information on the safety and tolerance of the buccal film in this patient group. The BUENA study enrolled 59 adults with mild to moderate severity AD, of which 52 completed 26 weeks treatment with “standard of care” cholinesterase inhibitors and Montelukast buccal film (10mg per day or 30mg twice daily) or cholinesterase inhibitors and placebo. Cognition was assessed using a battery of neuropsychological tests developed by Cogstate, a neuroscience company focused on optimizing cognitive assessment in clinical trials.
Related news for (IGXT)
- IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process
- IntelGenx Announces Initiation of the Sale and Investment Solicitation Process
- IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process
- IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives